Overview
Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.
Last reviewed: 17 June 2020
Diagnostics guidance 39 has been migrated to HealthTech guidance 544. The recommendations and accompanying content remain unchanged.
This guidance replaces the NICE medtech innovation briefing on NephroCheck test to help assess the risk of acute kidney injury in critically ill patients (MIB156).
Next review: This guideline will be reviewed if there is new evidence that is likely to change the recommendations.